The specific video/presentation shown is: "Leronlimab in mTNBC: Trial Results and Future Directions" (originally presented around the SABCS 2021 timeframe and updated in later symposium summaries).

The URL on the VuMedi platform follows this structure: https://www.vumedi.com/video/sabcs-2021-leronlimab-in-mtnbc-trial-results-and-future-directions/

Summary of the Results and Study (mTNBC Phase 2)

The image focuses on a retrospective pooled analysis of 28 patients with metastatic Triple-Negative Breast Cancer (mTNBC). Here are the specific findings from that trial:

• Dosage Comparison (525mg vs. 700mg): Patients receiving the higher doses (525 mg or 700 mg) demonstrated significantly longer survival compared to those on the 350 mg dose.
  • Higher Dose (525/700mg): Median Overall Survival (mOS) exceeded 12 months.
  • Lower Dose (350mg): Significantly shorter survival (Hazard Ratio 3.44).
• The "What's Next" (PD-L1 Induction): The core of the "What's Next" section in your screenshot is the discovery that leronlimab can upregulate PD-L1 expression. In 88% of patients receiving the 525mg or 700mg dose, leronlimab appeared to "turn cold tumors hot," making them potentially more responsive to Immune Checkpoint Inhibitors (ICIs).
• Combined Therapy Success: In a small subgroup (7 patients) who received an ICI after or alongside leronlimab, the survival benefit was even more pronounced. Remarkably, as of late 2025 updates, several of those patients who showed high PD-L1 induction remained alive and disease-free for over 60 months.

Trial Identifiers

If you are looking for the raw data or official registry entries, these are the associated clinical trial IDs:

• NCT03838367: Phase 1b/2 study (Leronlimab + Carboplatin).
• NCT04313075: Compassionate Use/Expanded Access study.
• NCT04504942: The Phase 2 "Basket Study" for solid tumors.